No.	Recommendations	GR	LoE	Sources
* Data on the effectiveness of consolidation or maintenance therapy to increase progression-free survival (PFS) is only available for bevacizumab (see 8.6.)
8.5.	The first-line chemotherapy for patients with advanced ovarian cancer (II b-IV) must consist of carboplatin AUC5 and paclitaxel 175 mg/m2 for 3 h i. v. over a total of 6 cycles, with one cycle every 3 weeks.	A	1++	Guidelines: 118, 119 Primary studies: 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131
8.6.	Additional therapy with bevacizumab can be considered in patients with advanced ovarian cancer (IIIB-IV).	0	1+	Primary studies: 132, 133
8.7.	Changes in dose density or intensity should only be done as part of a clinical trial.	B	1+	Guidelines: 2 Primary studies: 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146
8.8.	No maintenance or consolidation therapies must be carried out after primary therapy has been completed.*	A	1+	Primary studies: 132, 133, 147, 148, 149, 150, 151, 152, 153, 154
8.9.	Systematic recording of the patientʼs quality of life can be helpful to identify difficulties during treatment.	CC